BR112012030485A2 - composição para prevenção ou tratamento de osteoporose e processo de fabricação para a mesma - Google Patents

composição para prevenção ou tratamento de osteoporose e processo de fabricação para a mesma

Info

Publication number
BR112012030485A2
BR112012030485A2 BR112012030485A BR112012030485A BR112012030485A2 BR 112012030485 A2 BR112012030485 A2 BR 112012030485A2 BR 112012030485 A BR112012030485 A BR 112012030485A BR 112012030485 A BR112012030485 A BR 112012030485A BR 112012030485 A2 BR112012030485 A2 BR 112012030485A2
Authority
BR
Brazil
Prior art keywords
osteoporosis
composition
prevention
treatment
manufacturing process
Prior art date
Application number
BR112012030485A
Other languages
English (en)
Inventor
Chang-Kyoo
Sang-Geun Park
Tae-Won Lee
Original Assignee
Dream Pharma Corp
Navipharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dream Pharma Corp, Navipharm Co Ltd filed Critical Dream Pharma Corp
Publication of BR112012030485A2 publication Critical patent/BR112012030485A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

composição para prevenção ou tratamento de osteoporose e processo de fabricação para a mesma. é mostrada uma composição para a prevenção ou tratamento de osteoporose,compreendendo ácido ibandrônico, em seu sal ou hidratos farmaceuticamente aceitáveis, e vitamina d. devido ao ácido ibandrônico, o seu sal ou hidratos farmaceuticamente aceitáveis serem processados para exibirem propriedades físicas similares àquelas de vitamina d, a composição garante uniforme eficácia farmacêutica para as formulações preparadas a partir da mesma.
BR112012030485A 2010-06-10 2011-06-03 composição para prevenção ou tratamento de osteoporose e processo de fabricação para a mesma BR112012030485A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020100054921A KR101230178B1 (ko) 2010-06-10 2010-06-10 골다공증 예방 또는 치료용 조성물 및 이의 제조방법
PCT/KR2011/004067 WO2011155728A2 (ko) 2010-06-10 2011-06-03 골다공증 예방 또는 치료용 조성물 및 이의 제조방법

Publications (1)

Publication Number Publication Date
BR112012030485A2 true BR112012030485A2 (pt) 2016-08-09

Family

ID=45098503

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012030485A BR112012030485A2 (pt) 2010-06-10 2011-06-03 composição para prevenção ou tratamento de osteoporose e processo de fabricação para a mesma

Country Status (9)

Country Link
US (1) US9044401B2 (pt)
EP (1) EP2581086A4 (pt)
JP (1) JP5756172B2 (pt)
KR (1) KR101230178B1 (pt)
CN (1) CN102946884B (pt)
BR (1) BR112012030485A2 (pt)
CA (1) CA2798368C (pt)
MX (1) MX360235B (pt)
WO (1) WO2011155728A2 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101102364B1 (ko) * 2009-09-18 2012-01-03 한림제약(주) 비스포스포네이트 유도체 및 고용량의 콜레칼시페롤을 포함하는 약학 조성물
PT106978A (pt) * 2013-05-31 2014-12-02 Tecnimede Sociedade Tecnico Medicinal S A Composição sólida oral contendo ácido ibandrónico e vitamina d
MX2017009799A (es) * 2015-01-28 2018-01-18 Hanmi Pharm Ind Co Ltd Capsulas compuestas que comprenden raloxifeno y vitamina d o sus derivados.
KR101774690B1 (ko) * 2016-04-22 2017-09-05 알보젠코리아 주식회사 라록시펜과 비타민 d를 포함하는 복합제제
KR102136459B1 (ko) * 2018-06-08 2020-07-21 알보젠코리아 주식회사 바제독시펜과 비타민 d를 포함하는 복합제제
KR20210086463A (ko) 2019-12-30 2021-07-08 경북대학교 산학협력단 4-헥실레소르시놀을 유효성분으로 포함하는 골질환 예방 또는 치료용 약학조성물

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0998933A1 (de) 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Verfahren zur Herstellung von bisphosphonathaltigen pharmazeutischen Zusammensetzungen zur oralen Applikation
US20030195171A1 (en) * 2002-04-05 2003-10-16 Daifotis Anastasia G. Method for inhibiting bone resorption with an alendronate and vitamin D formulation
US20040097468A1 (en) * 2002-11-20 2004-05-20 Wimalawansa Sunil J. Method of treating osteoporosis and other bone disorders with upfront loading of bisphosphonates, and kits for such treatment
US7511028B2 (en) 2003-08-29 2009-03-31 Brookler Kenneth H Use of bisphosphonates for otosclerosis
KR20050110814A (ko) * 2004-05-19 2005-11-24 머크 앤드 캄파니 인코포레이티드 골 흡수를 억제하기 위한 조성물 및 방법
US20050261250A1 (en) * 2004-05-19 2005-11-24 Merck & Co., Inc., Compositions and methods for inhibiting bone resorption
CN1993134A (zh) * 2004-05-19 2007-07-04 默克公司 用于抑制骨吸收含有二膦酸（阿仑膦酸）和维生素d（胆钙化固醇）的组合物
CN1729950A (zh) * 2004-08-05 2006-02-08 龙桦兴业有限公司 具有生理检测功能的卫生用品及其检测方法
GB0616794D0 (en) * 2006-08-24 2006-10-04 Arrow Int Ltd Solid dosage form
WO2008026907A1 (es) 2006-08-29 2008-03-06 Espinosa Abdala Leopoldo De Je Composición farmacéutica que comprende ibandronato y vitamina d3 para el tratamiento de osteoporosis
US20100179110A1 (en) 2006-12-20 2010-07-15 Mostafa Akbarieh Composition Containing a Bisphosphonic Acid in Combination with Vitamin D
CN201200626Y (zh) * 2008-06-17 2009-03-04 黑龙江福和华星制药集团股份有限公司 一种含有二膦酸盐类片和维生素d片的片剂胶囊
KR101102364B1 (ko) * 2009-09-18 2012-01-03 한림제약(주) 비스포스포네이트 유도체 및 고용량의 콜레칼시페롤을 포함하는 약학 조성물
RU2012157127A (ru) 2010-07-06 2014-08-20 Навифарм. Ко., Лтд. Фармацевтическая композиция, содержащая дапоксетин, для перорального введения с замедленным высвобождением
KR101243747B1 (ko) 2010-07-08 2013-03-13 주식회사 네비팜 고함량 리세드론산 함유 골다공증 치료용 약학조성물
KR20120005228A (ko) 2010-07-08 2012-01-16 주식회사 네비팜 골다공증 치료용 비스포스폰산 함유 장용 약학조성물 및 그의 제조방법
KR101156054B1 (ko) 2011-09-05 2012-06-20 주식회사 네비팜 안정한 에페리손 함유 서방성 의약조성물
WO2013058527A2 (ko) 2011-10-18 2013-04-25 주식회사 네비팜 류코트리엔 길항제와 에피나스틴의 복합제제
KR101278572B1 (ko) 2011-10-18 2013-06-25 주식회사 네비팜 류코트리엔 길항제와 에피나스틴의 복합제제

Also Published As

Publication number Publication date
KR101230178B1 (ko) 2013-02-06
MX360235B (es) 2018-10-26
CN102946884B (zh) 2016-03-16
US9044401B2 (en) 2015-06-02
WO2011155728A3 (ko) 2012-05-03
CA2798368C (en) 2015-01-20
CN102946884A (zh) 2013-02-27
JP5756172B2 (ja) 2015-07-29
KR20110135168A (ko) 2011-12-16
EP2581086A4 (en) 2014-08-06
US20130096091A1 (en) 2013-04-18
MX2012014402A (es) 2013-02-01
JP2013528210A (ja) 2013-07-08
WO2011155728A2 (ko) 2011-12-15
EP2581086A2 (en) 2013-04-17
CA2798368A1 (en) 2011-12-15

Similar Documents

Publication Publication Date Title
MX2014000341A (es) Novedosos derivados de trifluoro-metil-oxadiazol y su uso en el tratamiento de enfermedades.
UA106634C2 (uk) Тверда фармацевтична дозована форма
IL223783B (en) Compound 1-converted indole for use in the treatment of a disease or condition, a pharmaceutical preparation containing the compound and use of the compound to prepare a medicine
GB201118656D0 (en) New compounds
EA201491060A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
BR112012030485A2 (pt) composição para prevenção ou tratamento de osteoporose e processo de fabricação para a mesma
BR112012010706A2 (pt) composto, composição farmacêutica, combinação do produto farmacêutico, uso de um composto, e, métodos para o tratamento de uma doença ou condição, e para inibir um bromodomínio
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
WO2011099832A3 (en) Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
BR112015014458A2 (pt) derivados de manose para o tratamento de infecções bacterianas
WO2011106729A3 (en) Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
PH12014501967A1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
WO2013147649A3 (ru) ИНГИБИТОРЫ СИГНАЛЬНОГО ПУТИ PI3K/AKT/IKK/NF-kB, ИХ ФАРМАЦЕВТИЧЕСКИ ПРИЕМЛЕМЫЕ СОЛИ И СОДЕРЖАЩИЕ ИХ КОМПОЗИЦИИ ДЛЯ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ ВИРУСНЫХ ЗАБОЛЕВАНИЙ
BRPI1007092B8 (pt) Derivados de hidroxamato, uso dos derivados de hidroxamato, composições farmacêuticas e método de produção de derivados de hidroxamato
MX2013003635A (es) Compuestos de n-heteroarilo.
MX2013004759A (es) Compuestos de oxima como agentes de elevacion de colesterol de lipoproteina de alta densidad (hdl).
EP2818172A4 (en) TLR4 MEDIUM, TISSUE HOMEOSTAT, HEPATOCYTE GROWTH FACTOR INDUCTOR, TISSUE-DISAPPEARING AGENT, AND SIRTUINE INDUCTOR WITH HYALURONIC ACID FRAGMENTS AS ACTIVE AGENTS THEREOF
EP2796450A4 (en) 6-AMINOPYRIDINE-3-OL DERIVATIVES OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, AND PHARMACEUTICAL COMPOSITION CONTAINING THESE DERIVATIVES OR THESE SALTS AS ACTIVE INGREDIENTS FOR THE PREVENTION OR TREATMENT OF ANGIOGENESIS DISEASES
MX367926B (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
BR112012024887A2 (pt) grânulos de quitosana, preenchedor, processo para preparar os grânulos de quitosana, kit e disposto de injeção
TN2014000031A1 (en) Use of organic compound for the treatment of noonan syndrome
WO2011102702A3 (en) Process for the preparation of oral solid dosage forms comprising valsartan
BR112013012100A2 (pt) composição ou formulação farmacêutica adaptada para administração oral em forma de comprimido, comprimido revestido ou cápsula na prevenção ou tratamento de distúrbios intestinais, processo para preparar a composição ou formulação farmacêutica e uso da composição ou formulação farmacêutica
WO2011058245A8 (fr) Nouveaux derives de mannopyranoside ayant une activite anticancereuse
BR112013005226A2 (pt) "n-fenetiltriazolonaacetamidas substituídas e o seu uso".

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: NAVIPHARM CO., LTD. (KR) , ALVOGEN KOREA CO.,LTD.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]